:: Volume 21, Issue 1 (1-2023) ::
Int J Radiat Res 2023, 21(1): 163-167 Back to browse issues page
Effective management of a patient with secondary male breast cancer after neck radiotherapy for tonsillar lymphoma
F. Tramacere , A.R. Pisani , E. Maggiulli , M. Moschetta , A. Sardaro , C. Altini , A. Sciacqua , M. Portaluri
Section of radiotherapy, DIM, University “Aldo Moro”, 70124 Bari, Italy , angelasardaro@libero.it
Abstract:   (706 Views)
Recent advances in surgical techniques, chemotherapy and radiotherapy led to significant increase in the number of long-term cancer survivors, but on other hand with increased probability of adverse effects, including the development of a secondary malignant neoplasm. This is especially important to consider when there is the need to provide treatment recommendations for patients undergoing radiotherapy keeping in mind the potential risks of toxicity associated with possession of specific genetic variants. We reported the clinical case of a patient in whom rare malignancies associated to genetic mutation have been treated and managed in the best way thanks to the support of radiotherapist. In particular a male patient with positive family history of BRCA2 mutation, developed breast cancer after radiotherapy for a rare tonsillar non-Hodgkin Lymphoma. We highlight that the knowledge of all aspects of the diseases, of all treatments secondary effects, in particular of ionizing radiation in patients with potential genetic risk of toxicity, allowed an optimal management of the case.
Keywords: Male breast cancer, BRCA2 mutation, secondary malignant neoplasm, non-Hodgkin lymphoma, radiation therapy.
Full-Text [PDF 579 kb]   (571 Downloads)    
Type of Study: Case Report | Subject: Radiation Biology
References
1. Ron E (1998) Ionizing radiation and cancer risk: evidence from epidemiology. Radiat Res, 150(5): S30-41. [DOI:10.2307/3579806]
2. Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, et al. (2012) Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst, 104(5): 357-70. [DOI:10.1093/jnci/djr533] [PMID] []
3. Moynahan ME, Pierce AJ, Jasin M (2001) BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell, 7(2): 263-72. [DOI:10.1016/S1097-2765(01)00174-5]
4. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, et al. (2015) ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 26(5): v116-25. [DOI:10.1093/annonc/mdv304] [PMID]
5. Genden EM, Ferlito A, Scully C, Shaha AR, Higgins K, Rinaldo A (2003) Current management of tonsillar cancer. Oral Oncol, 39(4): 337-42. [DOI:10.1016/S1368-8375(02)00085-4]
6. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, et al. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA, 290(4): 465-75. [DOI:10.1001/jama.290.4.465] [PMID]
7. Brennan P, Scélo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, et al. (2005) Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br J Cancer, 93(1): 159-66. [DOI:10.1038/sj.bjc.6602654] [PMID] []
8. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107(1): 108-15. [DOI:10.1002/cncr.21971] [PMID]
9. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, et al. (2008) Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica. 93(3): 398-404. [DOI:10.3324/haematol.12120] [PMID]
10. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer, 101(1): 51-7. [DOI:10.1002/cncr.20312] [PMID]
11. Ruddy KJ and Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 24(6): 1434-43. [DOI:10.1093/annonc/mdt025] [PMID]
12. Rudlowski C (2008) Male Breast Cancer. Breast Care (Basel), 3(3): 183-189. [DOI:10.1159/000136825] [PMID] []
13. Weiss JR, Moysich KB, Swede H (2005) Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev, 14(1): 20-6. [DOI:10.1158/1055-9965.20.14.1]
14. Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, et al. (1991) Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst, 83(12): 849-54. [DOI:10.1093/jnci/83.12.849] [PMID]
15. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY et al. (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res, 18(1): 15. [DOI:10.1186/s13058-016-0671-y] [PMID] []
16. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108(2): 171-82. [DOI:10.1016/S0092-8674(02)00615-3]
17. Ferrari C, Niccoli Asabella A, Merenda N, Altini C, Fanelli M, Muggeo P, De Leonardis F, Perillo T, Santoro N, Rubini G (2017) Pediatric Hodgkin Lymphoma. Medicine (Baltimore), 96(5): e5973. [DOI:10.1097/MD.0000000000005973] [PMID] []
18. Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M (2012) Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol, 19(10): 3199-204. [DOI:10.1245/s10434-012-2479-z] [PMID]
19. Cutuli B (2007) Strategies in treating male breast cancer. Expert Opin Pharmacother, 8(2): 193-202. [DOI:10.1517/14656566.8.2.193] [PMID]
20. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, et al. (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol, 28(12): 2114-22. [DOI:10.1200/JCO.2009.25.5729] [PMID] []
21. Darkeh MHSE and Azavedo E (2014) Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int J Clin Med, 5: 1068-86. [DOI:10.4236/ijcm.2014.517138]
22. Lavelli V, Ferrari C, Santo G, Altini C, Ballini A, Sardaro A, Fanelli M, Pisani AR, Nappi AG, Giudice G, Rubini G (2020) The Lymphoscintigraphic Study of Unpredictable Head and Neck Cutaneous Melanoma Lymphatic Drainage. Biomedicines, 8(4): 70. [DOI:10.3390/biomedicines8040070] [PMID] []
23. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, et al. (2017) Effect of axillary dissection vs no axillary dissection on 10-Year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA, 318(10): 918-926. [DOI:10.1001/jama.2017.11470] [PMID] []
24. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F (2019) Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat, 173(1): 37-48. [DOI:10.1007/s10549-018-4921-9] [PMID] []
25. Yu E, Stitt L, Vujovic O, Joseph K, Assouline A, Au J, Younus J, Perera F, Tai P (2013) Prognostic factors for male breast cancer: similarity to female counterparts. Anticancer Res, 33(5): 2227-31.
26. Henriques Abreu M, Henriques Abreu P, Afonso N, Pereira D, Henrique R, Lopes C (2016) Patterns of recurrence and treatment in male breast cancer: A clue to prognosis? Int J Cancer, 139(8): 1715-20. [DOI:10.1002/ijc.30225] [PMID]
27. Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, et al. (2014) ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Eur J Radiol, 83(10): 1925-33. [DOI:10.1016/j.ejrad.2014.05.037] [PMID]
28. Evangelista L, Bertagna F, Bertoli M, Stela T, Saladini G, Giubbini R (2016) Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results from a Bicentric Population. Curr Radiopharm, 9(2): 169-77. [DOI:10.2174/1874471008666150528111112] [PMID]
29. Niccoli Asabella A, Simone M, Ballini A, Altini C, Ferrari C, Lavelli V, De Luca R, Inchingolo F, Rubini G (2018) Predictive value of 18F-FDG PET/CT on survival in locally advanced rectal cancer after neoadjuvant chemoradiation. Eur Rev Med Pharmacol Sci, 22(23): 8227-8236.
30. Vadi SK, Mittal BR, Sood A, Singh G, Bal A, Parihar AS, Bhattacharya A, Basher RK, Kapoor R (2019) Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer. Nucl Med Commun, 40(1): 63-72. [DOI:10.1097/MNM.0000000000000928] [PMID] []



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 1 (1-2023) Back to browse issues page